Cardiogenic Shock
Cardiogenic Shock
Cardiogenic shock is the condition where the heart cannot pump sufficient blood to fulfill the physiological needs of the body, causing inadequate tissue perfusion and the resultant organ dysfunction. There is a very close association of this serious condition with acute myocardial infarction; however, cardiogenic shock can be due to many other cardiac pathologies.
Mechanism of Cardiogenic Shock
The pathophysiology of cardiogenic shock is complex and involves an interplay between decreased cardiac output, systemic hypoperfusion, and compensatory mechanisms.
The primary defect is an acute reduction in myocardial contractility, leading to:
- Decreased Stroke Volume: Impaired myocardial function reduces the heart's ability to eject blood effectively during systole.
- Increased Ventricular Filling Pressures: This is caused by poor ejection, resulting in pulmonary congestion and systemic venous hypertension.
- Systemic Hypeoprfusion: Inadequate cardiac output leads to decreased blood flow to vital organs, which worsens tissue hypoxia.
- Neurohormonal Activation: The body activates the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) to compensate for reduced perfusion. Initially, this is beneficial but prolongs activation, increasing afterload and myocardial oxygen demand, further deteriorating cardiac function.
Causes of Cardiogenic Shock
Cardiogenic shock may originate from many various cardiac abnormalities which can be broad categorized into several groups.
- Myocardial Causes
- Recent acute myocardial infarction (most frequent).[1]
- Severe myocarditis
- Cardiomyopathy, that is dilated or hypertrophic
- Mechanical Complications of Cardiac Lesions
- Papillary muscle rupture.
- Ventricular septal rupture.
- Acute mitral and aortic dysfunction
- Arrythmic Causes
- Life-threatening ventricular tachycardia
- Bradyarrythmias or heartblock
- Right Ventricle failure
- Acute pulmonary embolism.
- Acute right ventricular infraction.
Signs and Symptoms
The clinical presentation of cardiogenic shock varies with the severity.
Hemodynamic signs:
- Hypotension (systolic blood pressure <90 mmHg or a drop of >30 mmHg from baseline).
- Tachycardia as a compensatory mechanism.
- Low cardiac output indices (<2.2 L/min/m²).[2]
Organ Hypoperfusion:
- Altered mental status due to cerebral hypoperfusion.
- Cold, clammy skin and cyanosis.
- Decreased urine output (<30 mL/hour)
Pulmonary Congestion:
- Dyspnea and tachypnea.
- Bibasilar crackles on auscultation.
- Hypoxemia and orthopnea.
Jugular Venous Distension: Suggests increased central venous pressure.
Diagnosis
In cardiogenic shock, prompt diagnosis is important for the management. Evaluation includes:
Clinical Assessment
- History and physical examination can provide an idea about the possible causes of the problem.
Laboratory Tests
- Cardiac biomarkers like troponin and BNP
- Arterial blood gas to evaluate oxygenation and acid-base balance.
- Serum lactate is an indicator of tissue hypoperfusion.
Imaging
- Echocardiography is a key imaging modality in the assessment of myocardial function, valve integrity, and mechanical complications.[3]
- Chest X-ray for pulmonary congestion or structural abnormalities.
Hemodynamic Monitoring
- Pulmonary artery catheterization to measure pressures and cardiac output.
Management
The treatment of cardiogenic shock is aimed at restoring perfusion, addressing the underlying cause, and preventing organ damage. Management is usually a combination of pharmacological and mechanical interventions:
Initial Stabilization: Oxygen therapy to ensure adequate oxygenation.
Intravenous fluids: Given with caution to avoid worsening pulmonary congestion.
Pharmacological Therapy:
- Inotropes: Agents such as dobutamine or milrinone increase myocardial contractility and enhance cardiac output.
- Vasopressors: Norepinephrine is the most commonly used to maintain systemic vascular resistance and blood pressure.[4]
- Diuretics: May be required to control pulmonary congestion.
- Anticoagulation: In acute myocardial infarction or pulmonary embolism.
Mechanical Support:
- Intra-aortic Balloon Pump (IABP): Temporary hemodynamic support by reducing afterload and improving coronary perfusion.
- Veno-arterial Extracorporeal Membrane Oxygenation (VA-ECMO): Advanced circulatory and respiratory support in refractory cases.
- Left Ventricular Assist Devices (LVADs): For patients awaiting heart transplantation or as a bridge to recovery.
Definitive Treatment:
- Percutaneous Coronary Intervention (PCI): Necessary for revascularization in AMI-related cardiogenic shock.[5]
- Surgical Repair: Needed for mechanical complications such as valve ruptures or septal defects.
- Heart Transplantation: Indicated for end-stage heart failure that is unresponsive to other treatments.
Prognosis
Despite advancements in treatment, cardiogenic shock remains associated with high mortality rates. Early recognition, timely intervention, and a multidisciplinary approach are crucial to improving outcomes.
References
- ↑ Reynolds HR, Hochman JS. Cardiogenic shock: current concepts and improving outcomes. Circulation. 2008;117(5):686-697.
- ↑ Hochman JS, Sleeper LA, Webb JG, et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. N Engl J Med. 1999;341(9):625-634.
- ↑ Mebazaa A, Pörsti I, Toller W, et al. Management of acute heart failure and shock. Eur Heart J Suppl. 2016;18(suppl G):G44-G52.
- ↑ Levy B, Bastien O, Karim B, et al. Experts’ recommendations for the management of adult patients with cardiogenic shock. Ann Intensive Care. 2015;5(1):52.
- ↑ Thiele H, Ohman EM, de Waha-Thiele S, et al.Management of cardiogenic shock complicating myocardial infarction: an update 2019. Eur Heart J. 2019;40(32):2671-2683.